Grant of options

RNS Number : 7697D

Genedrive PLC

24 October 2022

 

24 October 2022

genedrive plc

("genedrive" or the "Company")

Grant of Options

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that on 21 October 2022 share options ("Options") were granted to members of its senior management team to acquire a total of 400,000 ordinary shares of 1.5p each ("Ordinary Shares") in the Company under the Company's Share Option Scheme.

The Options have been granted with an exercise price of 12.25p being equal to the closing price on the day before the grant and vest after a period of three years, subject to certain performance criteria being met through achieving revenue targets, achieving cash targets and completing certain strategic projects in the year ending 30 June 2025. The Options are exercisable over the period of 10 years from the date of grant.

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1.	Details of the person discharging managerial responsibilities / person closely associated
a.	Name	1.   Sarah Barnett 2. Jonathan Barber 3. Gino Miele 4. Colleen Phythian
2.	Reason for the notification
a.	Position/status	1.  Marketing Director 2.  Operations Director 3.  R&D Director 4.  Director of Quality & Regulation
a.	Initial notification /Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	genedrive plc
b.	LEI	213800ZYODIRZ87Y4K14
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	Options over ordinary shares of 1.5 pence each GB00B1VKB244
b.	Nature of the transaction	Grant of options pursuant to and in accordance with the terms of the Company's Share Option Scheme dated 29 November 2017
c.	Price(s) and volume(s)	PDMR Exercise price No of Options Sarah Barnett 12.25p 100,000 Jonathan Barber 12.25p 100,000 Gino Miele 12.25p 100,000 Colleen Phythian 12.25p 100,000
d.	Aggregated information Aggregated volume Price	N/A
e.	Date of the transaction	21 October 2022
f.	Place of the transaction	Outside a trading venue

For further details please contact:

genedrive plc	[phone]
David Budd: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser and Joint Broker)	[phone]
James Steel / Oliver Duckworth
finnCap (Joint Broker)	[phone]
Geoff Nash / George Dollemore / Nigel Birks / Alice Lane
Walbrook PR Ltd (Media Relations & Investor Relations)	[phone] or  [e-mail]
Anna Dunphy	[phone]

 

END

 

 

DSHMBBATMTTTBTT